{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006722","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.239903+00:00","generated_at":"2026-06-06T01:58:06.458981+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elite Pharma Q3 revenue up 68% to $15.5M; operating profit up 80% to $3.5M","bullets":["Revenue $15.5M for Q3 FY2024 ended Dec 31, 2023, +68% YoY from $9.2M.","Operating profit $3.5M, +80% YoY from $1.9M.","Growth attributable to sales of Elite Laboratories label products launched during FY2024.","Company to hold conference call Feb 15, 2024 at 11:30 AM EST."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006722","json":"https://secwatch.observer/filing/0001493152-24-006722.json","markdown":"https://secwatch.observer/filing/0001493152-24-006722.md","text":"https://secwatch.observer/filing/0001493152-24-006722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006722/0001493152-24-006722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006722/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:58:06.458981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b50278839d889cec99365120815e642f1f82a461","claim":"ELITE PHARMACEUTICALS INC /NV/ reported third quarter of fiscal year 2024 ended December 31, 2023 results: revenue $15.5 million.","evidence_excerpt":"Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006722/0001493152-24-006722-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal year 2024 ended December 31, 2023"},{"label":"Revenue","value":"$15.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}